IGI Therapeutics SA, a wholly-owned subsidiary of Ichnos Glenmark Innovation (IGI)—an alliance between Glenmark Pharma and Ichnos Sciences Inc.—has signed an exclusive licensing agreement with AbbVie ...

The U.S. market stands out with a projected USD 377.1 billion valuation by 2034, thanks to robust R&D and government support, enhancing treatment accessibility and precision oncology adoption. Dublin, ...

Biopharmaceutical company AbbVie maintains thousands of steam traps at its North American R&D and manufacturing sites. However, outdated and obsolete software and infrastructure limitations made ...

AbbVie, a global biopharmaceutical major, announced its entry into the Indian oncology market with the introduction of Venetoclax for the treatment of both acute myeloid leukaemia (AML) and chronic ...

AbbVie Inc . (NYSE: ABBV), a leading biopharmaceutical company with a market capitalization of $375 billion, has been navigating a complex landscape of challenges and opportunities as it transitions ...

AbbVie Inc . (NYSE: ABBV), a leading biopharmaceutical company with a market capitalization of $375 billion, has been navigating a complex landscape of challenges and opportunities as it transitions ...